 Lille France, Cambridge Massachusetts, United States, November 16, 2020 GENFIT Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that data on NIS4TM technology and the complete RESOLVE-IT Phase 3 NASH clinical trial were among those highlighted in five posters at The Liver Meeting Digital ExperienceTM TLMdX, the annual scientific congress of the American Association for the Study of Liver Diseases AASLD, that was held virtually from November 13 to November 16, 2020. 